Metal dipyrrin complexes as potential photosensitizers for photodynamic therapy

Synthesis, Characterization, and Biological Evaluation of the Polymeric Encapsulation of a Ruthenium(II) Polypyridine Complex with Pluronic F‐127/Poloxamer‐407 for Photodynamic Therapy Applications

“…The ability to produce singlet oxygen ( 1 O 2 ) was then investigated to confirm that oxygen is able to reach the compound and to interact with the excited state of the complex. For this purpose, the change in absorbance of the 1 O 2 scavenger 1,3‐diphenyl‐isobenzofuran was time dependently monitored upon irradiation at 500 nm . The results (Table S1) confirm that the particles ( Ru1 – Ru4 ) are able to generate 1 O 2 in a similar manner than the compound itself.…”

Phototherapeutic anticancer strategies with first-row transition metal complexes: a critical review

“…105 Finally, an attempt to design a Ni( ii ) complex as a PDT photosensitizer was published in 2020, but no 1 O 2 generation nor phototoxicity were observed. 113…”

“…105 Another Cu( ii ) complex was designed as a PS, but had a very poor ability to generate singlet oxygen: exposing the cells to light did not really change their viability. 113 To avoid Cu( ii ) reduction by thiols in cells, the use of Cu( i ) complexes could be another solution, that has only been scarcely explored, probably because of the instability of the majority of four-coordinated Cu( i ) complexes. In 2018, Khnayzer and co-workers published their work on a cuprous bis-phenanthroline complex for PDT applications ( Cu-12 ).…”

Ru(II) Polypyridine Complex-Functionalized Mesoporous Silica Nanoparticles as Photosensitizers for Cancer Targeted Photodynamic Therapy

“…Photodynamic therapy (PDT) has made its way inside the clinics to treat certain types of cancer. During such a treatment, a photosensitizer (PS) is exposed to a light source to photo-catalytically generate reactive oxygen species, which cause cellular damage. , Next to tetrapyrrolic compounds, which are currently applied in the clinics, metal complexes − and especially Ru­(II) polypyridine complexes − are extensively studied to complement the existing PDT PSs because of their ideal photophysical and biological properties. Due to the necessity of light activation, PDT treatments have intrinsically a first level of selectivity.…”